A Randomized, Controlled Trial Evaluating Efficacy of Perioperative Organ Protection as Well as Safety of Ulinastatin Use in Pediatric Patients Undergoing Open Heart Surgery Through CPB to Treat Complex Congenital Heart Diseases
Phase of Trial: Phase IV
Latest Information Update: 19 Jun 2017
At a glance
- Drugs Ulinastatin (Primary)
- Indications Congenital heart defects
- Focus Therapeutic Use
- Sponsors Techpool Bio-Pharma
- 13 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 13 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 14 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 May 2017.